23 July 2014 - 23 July 2014 - Neurotrope Bioscience Inc, part of US therapeutic and diagnostic technologies company Neurotrope Inc (OTCMKTS:NTRP), said yesterday it had exclusively licensed from Icahn School of Medicine at Mount Sinai results and data for the use of Bryostatin-1 in the treatment of Niemann-Pick Type C Disease (NPC), a rare, lysosomal storage disease.

Additionally, the licence involves other diseases and disorders that depend on activation of the enzyme, PKCepsilon, which is key to the health of some cells.

The development programme for Bryostatin-1 is being carried out together with Dr. Yiannis Ioannou, Professor of Genetics and Genomic Sciences at Mount Sinai. Neurotrope has already filed for a joint provisional patent in the USA covering the use and marketing of bryostatin technology for the treatment of Niemann-Pick Type C Disease.

As part of the licence deal, Mount Sinai will receive from Neurotrope an upfront licence fee, annual maintenance fee, as well as future payments based on predefined product development milestones. Neurotrope will also provide Mount Sinai with a part of consideration obtained from sub-licensees, in addition to a royalty on net sales of products.